ANABOLIChESKAYa TERAPIYa OSTEOPOROZA.TERIPAPARATID: EFFEKTIVNOST', BEZOPASNOST' I OBLAST' PRIMENENIYa
https://doi.org/10.14341/osteo2013232-40
Abstract
This review of the literature has been dedicated to experimental and clinical studies of mechanism of action and efficacy of 1—34 amino acid fragment of parathyroid hormone — teriparatide as well as others contries experience of its prescribtion. Teriparatide is an osteoanabolic agent which stimulates bone formation by affecting bone modeling and by stimulating bone remodeling. The effects on modeling lead to increased bone formation whereas the effects on bone remodeling lead to increased bone turnover. Thus, in its mode of action teriparatide differs from all others medicines currently available to treat osteoporosis. Daily subcutaneous injections of teriparatide are proved to be effective to prevent low-traumatic vertebral and non-vertebral fractures in postmenopausal women with the history of vertebral fractures. Teriparatide is effective to treat osteoporosis in male and even more effective than alendronate to treat glucocorticoid-induced osteoporosis. Due to high cost and some restriction related to the duration of therapy (up to 18 months in Russia and 24 months in others countries) teriparatide should be recommended to treat severe osteoporosis in patients with a history >1 moderate clinical vertebral fracture or two or more vertebral fragility fractures or in case the previous treatment was not effective. Teriparatide should be prescribed after bisphosphonates or other antiosteoporotic treatment, but not in the combination with bisphosphonates. The prescribtion of bisphosphonates after teriparatide is effective to maintaine and further improve the effect. Thus, teriparatide is effective to treat severe osteoporosis and osteoporosis resistant to other therapy.
References
1. Recklinghausen FD.: Die fibrose oder deformierende ositis, die osteomalazie und die osteoplastische carzinose in ihren gegenseitigen beziehungen.// Festchrift Rudolf Virchow. George Reimer, Berlin, 1891.
2. Bauer E, Aub J, Albright JF: Studies of calcium and phosphorus metabolism: study of bone trabeculae as readily available reserve supply of calcium. J. Experimental Medicine 1929 Vol. 49 pp. 145—162.
3. Selye H.: On the stimulation of new bone formation with parathyroid extract and irradiated ergosterol. J. Endocrinology 1932 Vol. 16, p. 547.
4. Белая Ж.Е., Рожинская Л.Я. «Возможности применения паратирео-идного гормона для лечения остеопороза» Ж. Остеопороз и остеопатии, 2004, №3 стр 26—33.
5. Habener JF, Potts JT : Biosynthesis of parathyroid hormone (Part 1). New England J. Medicine 1978 Vol. 299 pp. 580—585.
6. Habener JF, Potts JT: Biosynthesis of parathyroid hormone (Part 2). New England J. Medicine 1978 Vol. 299 pp. 635—644.
7. Potts JT, Bringhurst FR, Gardella T.: Parathyroid hormone: physiology, chemistry, biosynthesis, secretion, metabolism and mode of action. In: DeGroot LJ, Ed. Endocrinology 3rd edn. Philadelphia: WB Saunders 1995 Vol. 2 pp. 920—966.
8. Sato M, Zeng GQ, Turner CH.: Biosynthetic human parathyroid hormone (1-34) effects on bone quality in aged ovariectomized rats. J. Endocrinology 1997 Vol. 138, pp. 4330—4337.
9. Potts JT Jr, Murray TM, Peacock M. Niall HD., Tregear GW, Keutmann HT, Powell D., Deftos LJ.: Parathyroid hormone: sequence, synthesis, immunoassay studies. American J. Medicine 1971 Vol. 50 pp. 639—649.
10. Potts JT Jr.: The non-traditional actions of parathyroid hormone: status 1991, an overview. J. Endocrinology Investigation 1992 Vol. 15 pp. 3—9.
11. Jilka RL. Molecular and cellular mechanisms of the anabolic effect of intermittent PTH.// Bone, 2007, Vol. 40, pp. 1434—1446.
12. Bellido T, Ali AA, Gubrij I, Plotkin Li, Fu Q, O’Brien CA, et.al.: Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology, 2005, Vol. 146, pp. 4577—4583.
13. Keller H, Kneissel M.: SOST is a target gene for PTH in bone.// Bone, 2005, Vol. 37, pp. 148—158.
14. Guo J, Liu M, Yang D, Bouxsein ML, Saito H, Galvin RJ, et.al.: Suppression of Wnt signaling by Dkk1 attenuates PTH-mediated stromal cell response and new bone formation. Cell Metab, 2010, Vol. 11, pp. 161—171.
15. Robling AG, Kedlaya R, Ellis SN, Childress PJ, Bidwell JP, Bellido T, et.al. Anabolic and catabolic regimens of human parathyroid hormone 1-34 elicit bone- and envelop-specific attenuation of skeletal effects in SOST-deficient mice. Endocrinology, 2011, Vol. 152, pp. 2963—2975.
16. Rhee Y, Allen MR, Condon K, Lezkano V, Ronda AC, Galli C, et.al.: PTH receptor signaling in osteocytes governs periosteal bone formation and intracortical remodeling. J. Bone Mineral Res, 2011, Vol. 26, pp. 1035—1046.
17. Bedi B, Li JY, Tawfeek H, Baek KH, Adams J, Vangara SS, et.al.: Silencing of parathyroid hormone (PTH) receptor 1 in T cells blunts the bone anabolic activity of PTH. Proc Natl Acad Sci USA, 2012, Vol. 109, E725—733.
18. Wan M, Yang C, Li J, Wu X, Yuan H, Ma H, et.al.: Parathyroid hormone signaling through low-density lipoprotein-related ptrotein-6.// Genes Dev, 2008, Vol. 22, pp. 2968—2979.
19. Taurin S, Sandbo N, Qin Y, Browning D, Dulin NO.: Phosphorilation of beta-catenin by cyclic AMP-dependent protein kinase. J. Biol Chem, 2006, Vol. 281, pp. 9971—9976.
20. Jilka RL, Almeida M, Ambrogini E, Han L, Roberson PK, Weinstein RS, et.al.: Decreased oxidative stress and greater bone anabolism in the aged, when compared to the young , murine skeleton with parathyroid hormone administration. Aging Cell, 2010, Vol. 9, pp. 851—867.
21. Fei Y, Hurley MM.: Role of fibroblast growth factor 2 and Wnt signaling in anabolic effects of parathyroid on bone formation.// J. Cell Physiol, 2012, Vol. 227, pp. 3539—3545.
22. Marie PJ.: Signaling Pathways affecting skeletal health.// Curr Osteoporos Rep, 2012, Vol. 10, pp. 190—198.
23. McClung MR, Martin JS, Miller PD, Civitelli R, Bandeira F, Omizzo M, Donley DW, Dalsky GP, Eriksen EF.: Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass.//Arch Intern Med, 2005, Vol. 165, pp. 1762—1768.
24. Lindsay R, Cosman F, Zhou H, Bostrom MP, Shen VW, Cruz JD, Nieves JW, Dempster DW.: A novel tetracycline labeling schedule for longitudinal evaluation of the short-term effects of anabolic therapy with a single iliac crest bone biopsy: early actions of teriparatide.// J. Bone and Mineral Research, 2006, Vol. 21, pp. 366—373.
25. Белая Ж.Е., Рожинская Л.Я.: «Бисфосфонаты: мифы и реальность».// Ж. Эффективная фармакотерапия в эндокринологии, 2010, сентябрь, стр. 52—58.
26. Белая Ж.Е., Рожинская Л.Я.: «Бисфосфонаты в терапии постменопаузального остеопороза» Ж. Доктор Ру, 2010, Т.58 (№7), стр. 29—38.
27. Белая Ж.Е., Рожинская Л.Я. Новые направления в терапии остеопороза - применение моноклональных человеческих антител к RANKL (Деносумаб) // Ж. Остеопороз и Остеопатии, 2011, № 2, стр. 19—22.
28. Balena R, Toolan BC, Shea M, Markatos A, Myers ER, Lee SC, Opas EE , Seedor JG , Klein H, Frankenfield D : The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone hystomorphometry and bone strength in ovariectomized nonhuman primates. J. Clinical Investigation 1993 Vol. 92 pp. 2577—2586.
29. Draper MW, Flowers DE, Huster WJ, Neild JA, Harper KD, Arnaud C.: A controlled trial of raloxifene (LY139481) HCl: impact on bone turnover and serum lipid profile in healthy postmenopausal women. J. Bone Mineral Research 1996 Vol. 11, pp. 835—842.
30. Дедов ИИ, Рожинская ЛЯ, Белая ЖЕ «Роль и место бисфосфонатов в профилактике и лечении остеопороза 10-летний опыт применения алендроната, Ж. Остеопороз и остеопатии, 2005, № 1, стр. 20—30.
31. Торопцова НВ, Беневоленская ЛИ.: Результаты применения золедроновой кислоты в лечении остеопороза. Ж. Остеопороз и остеопатии, 2008, № 2, стр. 25—28.
32. Скрипникова ИА, Рожинская ЛЯ.: Применение дженериков - способ повышения приверженности лечению остеопороза. Ж.Остеопороз и остеопатии, 2010, №3, стр. 36—40.
33. Arlot M, Meunier PJ, Boivin G, Haddock L, Tamayo J, Correa-Rotter R, Jasqui S, Donley DW, Dalsky GP, San Martin J, Eriksen EF.: Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters.// JBMR, 2005, Vol. 20, pp. 1244—1253.
34. McClung MR, Martin JS, Miller PD, Civitelli R, Bandeira F, Omizzo M, Donley DW, Dalsky GP, Eriksen EF.: Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass.//Arch Intern Med, 2005, Vol. 165, pp. 1762—1768.
35. Dempster DW, Zhou H, Recker RR, Brown JP, Bolognese MA, Recknor CP, Kendler DL, Lewiecki EM, Hanley DA, Rao DS, Miller PD, Woodson GC, Lindsay R, Binkley N, Wan X, Ruff VA, Janos B, Taylor KA.: Skeletal histomorphometry in subjects on teriparatide or zoledronic acid therapy (SHOTZ) study: a randomized controlled trial.//J. Clin Endocrinol Metabolism, 2012, Vol. 97, pp. 2799—2808.
36. Canalis E, Hott M, Deloffre P, Tsouderos Y, Marie PJ.: The divalent strontium salt S12911 enhances bone cell replication and bone formation in vitro. Bone, 1996, Vol. 18, pp. 517—523.
37. Takahashi N, Sasaki T, Tsuoderos Y, Suda TS.: 12911-2 inhibits osteoclastic bone resorption in vitro. // J. Bone Mineral Research, 2003, Vol. 18, pp. 1082—1087.
38. Rogers MJ.: New insights into the molecular mechanisms of action of bisphosphonates. // Curr Pharm Des, 2003, Vol. 12, pp. 2643—2658.
39. Meunier PJ, Slosman DO, Delmas PD, Sebert JL, Brandi ML, Albanese C, Lorenc R, Pors-Nielsen S, Roges VA, Reginster JY.: Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis - a 2-year randomized placebo controlled trial.// JCEM, 2002, Vol. 87, pp. 2060—2066.
40. Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, Cannata J, Balogh A, Lemmel EM, Pors-Nielsen S, Rizzoli R, Genant HK, Reginster JY.: The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis.// N. Engl J. Med, 2004, Vol. 350, pp. 459—468.
41. Recker RR, Marin F, Ish-Shalom S, Moricke R, Hawkins F, Kapetanos G, Pena MP, Kekow J, Farrerons J, Sanz B, Oertel H, Stepan J.: Comparative effects of teriparatide and strontium ranelate on bone biopsies and biochemical markers of bone turnover in postmenopausal women with osteoporosis.// JBMR, 2009, Vol. 24, pp. 1358—1368.
42. Kanis J.A, McCloskey EV, Johansson H, Cooper C, Rizolli R, Reginster R, on behalf of the Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committee of Scientific Advisors of the International Osteoporosis Foundation (IOF).: European guidance for the diagnosis and management of osteoporosis in postmenopausal women.// Osteoporosis International, 2013, Vol. 24, pp. 23—57.
43. Blake GM, Fogelman I.: Effect of bone strontium on BMD measurements.// J. Clinical Densitometry, 2007, Vol. 10, pp. 34—38.
44. Blake GM, Lewiecki EM, Kendler DL, Fogelman I.: A review of strontium ranelate and its effect on DXA scans.// J. Clinical Densitometry, 2007, Vol. 10, pp. 113—119.
45. Nielsen SP, Slosman D, Sorensen OH, Basse-Cathalinat B, De Cassin P, Roux C, Meunier PJ.: Influence of strontium on bone mineral density and bone mineral content measurements by dual X-ray absorptiometry.// J. Clinical Densitometry, 1999, Vol. 2, pp. 371—379.
46. Blake GM, Compston JE, Fogelman I.: Could strontium ranelate have a synergistic role in the treatment of osteoporosis?// JBMR, 2009, Vol. 24, pp. 1354—1357.
47. Stepan JJ.: Strontium ranelate: in search for the mechanism of action.// J. Bone Miner Metab, punlished online 09 August 2013.
48. Рожинская Л.Я. «Системный остеопороз» Москва, изд. Мокеев, 2000 195стр.
49. Белая ЖЕ, Рожинская ЛЯ, Ильин АВ, Сазонова НИ, Алексеева ТМ, Дорофеева ОК, Попова ВГ: Эффективность профилактики остеопении препаратами кальция и витамина Д (Кальций Д3 Никомед форте) у женщин в постменопаузе с субклиническим тиреотоксикозом.// Ж. Остеопороз и остеопатии, 2007, № 2, стр. 13—18.
50. European Medicines Agency.: Recommendation to restrict the use of Protelos/Osseor (strontium ranelate) 25 April 2013 EMA/258269/2013.
51. European Medicines Agency: Questions and answers on the review of Protelos and Osseor (strontium ranelate) 15 March 2012 EMA/18304/2012.
52. Jonville-Bera AP, Autrer-Leca E.: Adverse drug reactions of strontium ranelate (Protelos in France).: Presse Med., 2011, Vol. 40, pp. E 453—462.
53. Watts NB, Bilezikian JP, Camacho PM, Greenspan SL, Harris ST, Hodgson SF, Kleerekoper M, Luckey MM, McClung MR, Pollack RP, Petak SM.: American Association of clinical endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of postmenopausal osteoporosis.// Endocrine Practice, 2010, Vol. 16, suppl 3, pp. 1—37.
54. Compston J, Bowring C, Cooper A, Cooper C, Davies C, Francis R, Kanis JA, Marsh D, McCloskey EV, Reid DM, Selby P.: Diagnosis and management of osteoporosis in postmenopaual women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013.// Maturitas, 2013, epub ached of print.
55. Papaioannou A, Morin S, Cheung AM, Atkinson S, Brown JP, Feldman S, Hanley DA, Hodsman A, Jamal SA, Kaiser SM, Kvern B, Siminoski K, Leslie WD for the Scientific Advisory Council of Osteoporosis Canada.: 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary.// CMAJ, 2010, Vol. 182, pp. 1864—1873.
56. Kanis JA, on behalf of the World Health Organization Scientific Group. Assessment of osteoporosis at the primary health care level. Technical report. University of Sheffield, UK, WHO Collaborating Centre, 2008.
57. Kanis JA.: Diagnosis of osteoporosis and assessment of fracture risk. Lancet, 2002, Vol. 359, pp. 1929-—1936.
58. Lindsay R, Silverman SL, Cooper C, Hanley DA, Barton I, Broy SB, Licata A, Benhamou L, Geusens P, Flowers K, Stracke H, Seeman E.: Risk of new vertebral fracture in the year following a fracture.//JAMA. 2001, Vol. 285, pp.320—323.
59. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH.: Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis./ England J. Medicine 2001 Vol.35 pp. 1434—1441.
60. Gallagher JC, Genant HK, Crans GG, Vargas SJ, Krege JH.: Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures.// J. Clinical Endocrinology Metabolism, 2005, Vol. 90, pp. 1583—1587.
61. Marcus R, Wang O, Satterwhite J, Mitlak B.: The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis./ J. Bone Mineral Research. 2003 Vol.18 pp.18—23.
62. Prevrhal S, Krege JH, Chen P, Genant H, Black DM.: Teriparatide vertebral fracture risk reduction determined by quantitative and qualitative radiographic assessment.// Current Medical Research Opinion, 2009, Vol. 25, pp. 921—928.
63. Gallagher JC, Rosen CJ, Chen P, Misurski DA, Marcus A.: Response rate of bone density to teriparatide in postmenopausal women.// J. Bone, 2006, Vol. 39, pp. 1268.
64. Delmas PD, Licata AA, Reginster JY, Crans GG, Chen P, Misurski DA, Wagman RB, Mitlak BH.: Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover.// J. Bone, 2006, Vol. 39, pp. 237—243.
65. Eastell R, Krege JH, Chen P, Glass EV, Reginster JY. : Development of an algorithm for using PINP to monitor treatment of patients with teriparatide.// Curr Med Res Opin, 2006, Vol. 22, pp. 61—66.
66. Dobnig H, Sipos A, Jiang Y, Fahrleitner-Pammer A, Ste-Marie LG, Gallagher JC, Pavo I, Wang J, Eriksen EF.: Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy.// J. Clinical Endocrinology Metabolism, 2005, Vol. 90, pp. 3970—3977.
67. Chen P, Miller PD, Delmas PD, Misurski DA, Krege JH.: Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis.// J. Bone Mineral Research, 2006, Vol. 21, pp. 1785—1790.
68. Zanchetta JR, Bogardo CE, Ferretti JL, Wang O, Wilson MG, Sato M, Gaich GA, Dalsky GP, Myers SL.: Effects of Teriparatide [Recombinant Human Parathyroid Hormone (1-34)] on cortical bone in postmenopausal women with osteoporosis. J. Bone and Mineral Research 2003 Vol. 18 pp.539—543.
69. Graeff C, Timm W, Nickelsen TN, Farrerons J, Marin F, Barker C, Gluer CC.: Monitoring teriparatid-associated changes in vertebral microstructure by high-resolution CT in vivo: results from the EUROFORS study.// J. Bone Mineral Research, 2007, Vol. 22, pp. 1426—1433.
70. Uusi-Rasi K, Semanick LM, Zanchetta JR, Bogado CE, Eriksen EF, Sato M, Beck TJ.: Effects of teriparatide [rhPTH (1-34)] on structural geometry of the proximal femur in elderly osteoporotic women.// J. Bone, 2005, Vol. 36, pp. 948—958.
71. Jiang Y, Zhao JJ, Mitlak BH, Wang O, Genant HK, Eriksen EF.: Recombinant human Parathyroid hormone (1-34) [Teriparatide] improves both cortical and cancellous bone structure./ J. Bone and Mineral Research 2003 Vol. 18 pp. 1932—1941.
72. Graeff C, Chevalier Y, Charlebois M, Varga P, Pahr D, Nickelsen TN, Morlock MM, Gluer CC, Zysset PK.: Improvement in vertebral body strength under teriparatide treatment assessed in vivo by finite element analysis: results from the EUROFORS study.// JBMR, 2009, Vol. 24, pp. 1672—1680.
73. Ma YL, Zeng Q, Donley DW, Ste-Marie LG, Gallagher JC, Dalsky GP, Marcus R, Eriksen EF. : Teriparatide increases bone formation in modeling and remodeling osteons and enhances IGF-II immunoreactivity in postmenopausal women with osteoporosis.// J. Bone Mineral Research, 2006, Vol. 21, pp. 855—864.
74. Peschalis EP, Glass EV, Donley DW, Eriksen EF.: Bone mineral and collagen quality in iliac crest biopsies of patients given teriparatide: new results from the fracture prevention trial.// J. Clinical Endocrinology and Metabolism, 2005, Vol. 90, pp. 4644—4649.
75. Genant HK, Halse J, Briney WG, Xie L, Glass EV, Krege JH.: The effects of teriparatide on the incidence of back pain in postmenopausal women with osteoporosis.// J. Curr Med Res Opin, 2005, Vol. 21, pp. 1027—1034.
76. Nevitt MC, Chen P, Kiel DP, Reginster JY, Dore RK, Zanchetta JR, Glass EV, Krege JH.: Reduction in the risk of developing back pain persists at least 30 months after discontinuation of teriparatide treatment: a meta-analysis.// J. Osteoporosis International, 2006, Vol. 17, pp. 1630—1637
77. Prince R, Sipos A, Hossain A, Syversen U, Ish-Shalom S, Marcinowska E, Halse J, Lindsay R, Dalsky GP, Mitlak BH.: Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment.// J. Bone Mineral Research, 2005, Vol. 20, pp. 1507—1413.
78. Fahrleitner-Pammer A, Langdahl BL, Marin F, Jakob F, Karras D, Barret A, Ljunggren O, Walsh JB, Rajzbaum G, Barker C, Lems WF.: Fracture rate and back pain during and after discontinuation of teriparatide: 36 month data from the European Forsteo Observational Study (EFOS).// Osteoporosis International, 2011, Vol. 22, pp. 2709—2719.
79. Lindsay R, Miller P, Pohl G, Glass EV, Chen P, Krege JH. Relationship between duration of teriparatide therapy and clinical outcomes in postmenopausal women with osteoporosis // Osteoporosis Int, 2009, Vol. 20, pp. 943—948.
80. Рожинская Л.Я., Арапова СД, Дзеранова ЛК, Молитвословова Н.Н., Ильин А.В., Сазонова Н.И., Чернова ТО., Шишкина А.А., Дедов И.И., Беневоленская Л.И., Никитинская О.А., Короткова ТА., Торопцова Н.В., Смирнов А.В., Дёмин Н.В., Николенко В.К., Брижань Л.К., Цибина Л.В.: Исследование эффективности и безопасности терапии терипаратидом (Форстео) в течение 1 года при постменопаузальном остеопорозею.// Ж. Остеопороз и остеопатии, 2006, Том 2, стр. 6—12.
81. Orwoll ES, Scheele WH, Paul S, Adami S, Syversen U, Diez-Perez A, Kaufman JM, Clancy AD, Gaich GA.: The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis./ J. Bone Mineral Research 2003 Vol.18 pp. 9.
82. Saag KG, Shane E, Boonen S, Marin F, Donley DW, Taylor KA, Dalsky GP, Marcus R.: Teriparatide or alendronate in glucocorticoid-induced osteoporosis.// New England J. Medicine, 2007, Vol. 357, pp. 2028—2039.
83. Saag KG, Zanchetta JR, Devogelaer JP, Adler RA, Eastell R, See K, Krege JH, Krohn K, Warner MR.: Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of randomized, double-blind, controlled trial. Arthritis Rheum, 2009, Vol. 60, pp. 3346—3355.
84. Lane NE, Sanchez S, Modin GW, Genant HK, Pierini E, Arnaud CD.: Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. /J. Clinical Investigation 1998 Vol.102 pp.1627—33.
85. Rehman Q, Lang TF, Arnaud CD, Modin GW, Lane NE.: Daily treatment with parathyroid hormone is associated with an increase in vertebral cross-sectional area in postmenopausal women with glucocorticoid-induced osteoporosis./ J. Osteoporosis Internal 2003 Vol.14 pp. 77—81.
86. Belaya ZE Should we really compare absolute risk reduction in different trials on osteoporosis: comment on the article by Ringe JD and Doherty JG.// J. Rheumatology International 2011 Dec;31(12) pp.1669—1671.
87. Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, et.al.: Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Interventional Trial. J. Clin Endocrinol Metab, 2000, Vol. 85, pp. 4118—4124.
88. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, et.al: Once-Yearly Zoledronic acid for treatment of postmenopausal osteoporosis.// New England J. Medicine, 2007, Vol. 356, pp. 1809—1822.
89. Chesnut CH, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, Felsenberg D, Huss H, Gilbride J, Schimmer RC, Delmas PD.: Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.// J. Bone Miner Res, 2004, Vol. 19, pp. 1241—1249.
90. Cummings SR, Martin JS, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C, for the FREEDOM Trial: Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis.// New England J. Medicine, 2009, Vol.361, pp. 756—765.
91. European Medicines Agency Press Office. EMEA recommends changes in the product Information for Protelos/Osseor due to the risk of severe hypersensitivity reactions. EMEA/417458/2007.
92. Cacoub P, Descamps V, Meyer O, Speirs C, Belissa-Mathiot P, Musette P: Drug rash with eosinophilia and systemic symptoms (DRESS) in patients receiving strontium ranelate.// Osteoporosis International, 2013, Vol. 24, pp. 1751—1757.
93. Body JJ, Gaich GA, Scheele WH, Kulkarni PM, Miller PD, Peretz A, Dore RK, Correa-Rotter R, Papaioannou A, Cumming DC, Hodsman AB.: A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis./ J Clinical Endocrinology and Metabolism 2002 Vol. 87 pp. 4528.
94. Hadji P, Zanchetta JR, Russo L, Recknor CP, Saag KG, McKiernan FE, Silverman SL, Alam J, Burge RT, Krege JH, Lakshmanan MC, Masica DN, Mitlak BH, Stock JL.: The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fracture. Osteoporosis Int, 2012, Vol.23, pp. 2141—2150.
95. Keaveny TM, McClung MR, Wan X, Kopperdahl DL, Mitlak BH, Krohn K.: Femoral strength in osteoporotic women treated with teriparatide or alendronate.// Bone, 2012, Vol. 50, pp. 165—170.
96. Diez-Perez A, Adachi JD, Agnusdei D, Bilezikian JP, Compston JE, Cummings SR, Eastell R, Eriksen EF, Gonzales-Macies J, Liberman UA, Wahl DA, Seeman E, Kanis JA, Cooper C.: Treatment failure in osteoporosis.// Osteoporosis Int, 2012, Vol. 23, pp. 2769—2774.
97. Jakob F, Oertel H, Langdahl B, Ljunggren O, Barrett A, Karras D, Walsh JB, Fahrleintner-Pammer A, Rajzbaum G, Barker C, Lems WF, Marin F.: Effects of teriparatide in postmenopausal women with osteoporosis pre-treated with bisphosphonates: 36-month results from the European Forsteo Obsrevational Study.// European J. Endocrinology, 2012, Vol. 166, pp. 87—97.
98. Boonen S, Marin F, Obermayer-Pietsch B, Simoes ME, Barker C, Glass EV, Hadji P, Lyritis G, Oertel H, Nickelsen T, McCloskey EV.: Effects of previous antiresorbtive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis.// J. Clin Endocrinol Metab, 2008, Vol. 93, pp. 852—860.
99. Obermayer-Pietsch BM, Marin F, McCloskey EV, Hadji P, Farrerons J, Boonen S, Aurdan M, Barker C, Anastasilakis AD, Fraser WD, Nickelsen T.: Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorbtive treatment.// JBMR, 2008, Vol. 23, pp. 1591—1600.
100. Ettinger B, Martin JS, Crans G, Pavo I.: Differential effects of Teriparatide on BMD after treatment with Raloxifene or Alendronate. / J. Bone and Mineral Research 2004 Vol. 19 pp. 745—751.
101. Rittmaster rS, Bolognese M, Ettinger MP, Hanley DA, Hodsman AB, Kendler DL, Rosen CJ.: Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab. 2000 Vol. 85 pp.2129—34.
102. Eastell R, Nickelsen T, Marin F, Barker C, Hadji P, Farrerons J, Audran M, Boonen S, Brixen K, Comes JM, Obermayer-Pietsch B, Avramidis A, Sigurdsson G, Gluer CC.: Sequential treatment of severe postemenopausal osteoporosis after teriparatide: final results of the randomized, controlled European study of Forteo (EUROPORS).// JBMR, 2009, Vol. 24, pp. 726—736.
103. Black DM, Greenspan S.L., Ensrud K.I., Palermo L., McGowan JA, Lang TF., Garnero P, Bouxsein M.L., Bilezikian JP, Rosen CJ.: The effects of Parathyroid hormone and Alendronate alone or in combination in postmenopausal osteoporosis./ The New England J Medicine 2003 Vol.349 pp. 1207—1215.
104. Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM.: The effects of parathyroid hormone, alendronate, or both in men with osteoporosis./ The New England J Medicine 2003 Vol.349 pp. 1216—26.
105. Cosman F, Ericksen EF, Recknor C, Miller PD, Guanabens C, Kasperk C, Papanastasiou P, Readie A, Rao H, Gasser JA, Bucci-Rechtweg C, Boonen S.: Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34) in postmenopausal osteoporosis.// JBMR, 2011, Vol. 26, pp. 503—511.
106. Tsai JN, Uihlein AV, Lee H, Kumbhani R, Siwila-Sackman E, McKay EA, Burnett-Bowie SA, Neer RM, Leder BZ. Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial.//Lancet. 2013 Vol. 382(9886):pp,50—56.
107. Tashjian AH, Chabner BA.: Commentary on clinical safety of recombinant human parathyroid hormone 1-34 in the treatment of osteoporosis in men and postmenopausal women. / J. Bone and Mineral Research 2002 Vol. 17 pp. 1151—1161.
108. Vahle J.L., Sato M., Long GG, Young J.K., Francis PC, Engelhardt JA, Westmore MS, Ma YL, Nold JM.: Skeletal Changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety./ J. Toxicologic Pathology 2002 Vol. 30 pp. 312—321.
109. Miller PD, Schwartz EN, Chen P, Misurski DA, Krege JH.: Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment.// Osteoporosis International, 2007, Vol. 18, pp. 59—68.
110. Burr DB, Hirano T, Turner CH, Hotchkiss C, Brommage R, Hock JM: Intermittently administered human parathyroid hormone (1-34) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariectomized cynomolgus monkeys./ J. Bone Mineral research 2001 Vol. 16 pp. 157—165.
111. Smeland S, Muller C, Alvegard TA et al. Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders./ European J. Cancer 2003 Vol.39 pp. 488-94.
Review
For citations:
BELAYa Zh.E., ROZhINSKAYa L.Ya. ANABOLIChESKAYa TERAPIYa OSTEOPOROZA.TERIPAPARATID: EFFEKTIVNOST', BEZOPASNOST' I OBLAST' PRIMENENIYa. Osteoporosis and Bone Diseases. 2013;16(2):32-40. (In Russ.) https://doi.org/10.14341/osteo2013232-40
Views:
8764
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
